-
Featured News
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Featured News
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
-
Featured News
Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee
-
Featured News
Novartis sabatolimab receives orphan drug designation from the European Commission for myelodysplastic syndromes
-
Featured News
FDA accelerates review of Novartis STAMP inhibitor asciminib (ABL001) for patients with chronic myeloid leukemia (CML)
-
Featured News
Asia Pacific Patient Innovation Summit examines capability building gaps of Patient Organizations
-
Featured News
Novartis receives FDA Orphan Drug Designation for NIS793 in pancreatic cancer
-
Featured News
Beacon of Hope: Addressing health disparities through holistic community-based collective action
-
Featured News
Novartis announces Complete Response Resubmission for inclisiran New Drug Application
-
Featured News
Novartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Featured News
Novartis Entresto® indicated for treatment of hypertension in China
-
Featured News
One billion antimalarial treatments delivered: An extraordinary partnership journey